Search
  1. Home
  2. Africa
  • News

Anti-AIDS drug price-cut announced

    JOHANNESBURG

    Developing countries will be paying less for two anti-AIDS drugs produced by multinational pharmaceutical company, Gilead Sciences.
    In a statement Gilead said it had dropped the cost of Viread by 31 percent and that of Truvada by 12 percent. Both medications are already sold at no-profit prices in 97 developing countries around the world.

    According to the company, the no-profit price of a 30-day supply of Viread was now US $17, while a one-month supply of Truvada cost $26.25.

    However, Gilead stressed that only countries enrolled in the company's antiretroviral access programme would benefit from the price-cut.

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join